NASDAQ:PSNLPersonalis Stock Price, Forecast & News

Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PSNL stock has increased by 121.8% and is now trading at $13.35. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Personalis.

Personalis is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Personalis.

Personalis (NASDAQ:PSNL) issued its earnings results on Thursday, May, 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.03. The firm earned $19.16 million during the quarter, compared to analysts' expectations of $16.80 million. Personalis had a negative return on equity of 26.28% and a negative net margin of 40.60%. View Personalis' earnings history.

5 Wall Street analysts have issued 12 month target prices for Personalis' shares. Their forecasts range from $14.00 to $29.00. On average, they anticipate Personalis' share price to reach $22.25 in the next twelve months. This suggests a possible upside of 66.7% from the stock's current price. View analysts' price targets for Personalis.

News articles about PSNL stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Personalis earned a news impact score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutPersonalis.

Personalis saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,500,000 shares, a decrease of 11.2% from the April 30th total of 1,690,000 shares. Based on an average daily volume of 373,900 shares, the days-to-cover ratio is presently 4.0 days. Approximately 9.2% of the shares of the company are sold short. View Personalis' Current Options Chain.

Some companies that are related to Personalis include CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC), Miragen Therapeutics (MGEN), Psychemedics (PMD), OpGen (OPGN) and Avant Diagnostics (AVDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Editas Medicine (EDIT), Canopy Growth (CGC), Ford Motor (F), Flexion Therapeutics (FLXN), Proteostasis Therapeutics (PTI), Enphase Energy (ENPH), Energy Transfer LP Unit (ET), Inovio Pharmaceuticals (INO), NIO (NIO) and Viking Therapeutics (VKTX).

(PSNL) raised $100 million in an initial public offering (IPO) on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

Personalis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (4.95%), BlackRock Inc. (4.81%), Nikko Asset Management Americas Inc. (3.86%), Nikko Asset Management Americas Inc. (3.86%), Sumitomo Mitsui Trust Holdings Inc. (3.86%) and Wellington Shields Capital Management LLC (1.75%). Company insiders that own Personalis stock include Ken Ludlum, Lightspeed Venture Partners Se and Richard Chen. View institutional ownership trends for Personalis.

PSNL stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Nuveen Asset Management LLC, Squarepoint Ops LLC, and Alambic Investment Management L.P.. View insider buying and selling activity for Personalis.

PSNL stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Wellington Shields Capital Management LLC, Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Gabelli Funds LLC, and State Street Corp. Company insiders that have bought Personalis stock in the last two years include Ken Ludlum, and Lightspeed Venture Partners Se. View insider buying and selling activity for Personalis.

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PSNL stock can currently be purchased for approximately $13.35.

Personalis has a market capitalization of $423.33 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe.

The official website for Personalis is www.personalis.com.

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]